Retatrutide's FDA Approval Timeline for Weight Loss Drug Uncertain | Retatrutide News

Retatrutide, a weight loss drug in Eli Lilly's pipeline, is projected for FDA approval in 2026. The drug is part of the GLP-1 agonist class, which is ga...
Market News · October 10, 2026